Company
Pharmasum Therapeutics
- Biotech
- Location:
- Oslo, Norway
Description
Pharmasum Therapeutics discovers and develops neurological-disease drugs, including PST-674, a proprietary DYRK1A inhibitor intended to address dementia biology, with a planned proof-of-concept study in people with Down syndrome and dementia.
Pharmasum Therapeutics is located in the Oslo ecosystem.
Related
ADmit THERAPEUTICSADmit THERAPEUTICS develops and commercializes MAP-AD®, an in vitro diagnostic test using mitochondrial DNA epigenetic biomarkers, NGS and…
BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…
STORM TherapeuticsSTORM Therapeutics develops small molecule inhibitors of RNA-modifying enzymes, including STC-15, a METTL3 inhibitor in clinical…
Rab DiagnosticsRab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma…
ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
molecule.onemolecule.one builds the Maria AI platform, combining frontier chemistry models, a micro-liter high-throughput experimentation lab, and…
AntabioAntabio develops antibacterial therapies for multidrug-resistant Gram-negative infections and advances Meropenem-Pilabactam, a…
BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
Age LabsAge Labs develops biomarkers and predictive algorithms for early detection of age-related diseases, offering diagnostic tests, biological…